{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T18:32:30Z","timestamp":1778005950156,"version":"3.51.4"},"reference-count":2,"publisher":"American Medical Association (AMA)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA"],"published-print":{"date-parts":[[2023,2,28]]},"DOI":"10.1001\/jama.2022.22870","type":"journal-article","created":{"date-parts":[[2023,2,28]],"date-time":"2023-02-28T16:01:27Z","timestamp":1677600087000},"page":"684","source":"Crossref","is-referenced-by-count":1,"title":["Cefepime\/Enmetazobactam vs Piperacillin\/Tazobactam and Complicated Urinary Tract Infection or Acute Pyelonephritis"],"prefix":"10.1001","volume":"329","author":[{"given":"Chi-Kuei","family":"Hsu","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, E-Da Hospital, Kaohsiung, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen-Wen","family":"Tsai","sequence":"additional","affiliation":[{"name":"Department of Education, Chi Mei Medical Center, Tainan, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chih-Cheng","family":"Lai","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Chi Mei Medical Center, Tainan, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10","reference":[{"issue":"13","key":"jle220166r1","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1001\/jama.2022.17034","article-title":"Effect of cefepime\/enmetazobactam vs piperacillin\/tazobactam on clinical cure and microbiological eradication in patients with complicated urinary tract infection or acute pyelonephritis: a randomized clinical trial.","volume":"328","author":"Kaye","year":"2022","journal-title":"JAMA"},{"key":"jle220166r2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciac688","article-title":"Breaking down the breakpoints: rationale for the 2022 Clinical and Laboratory Standards Institute revised piperacillin-tazobactam breakpoints against Enterobacterales.","author":"Tamma","journal-title":"Clin Infect Dis"}],"container-title":["JAMA"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/articlepdf\/2801857\/jama_hsu_2023_le_220166_1676659360.13186.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,28]],"date-time":"2023-02-28T16:01:31Z","timestamp":1677600091000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2801857"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,28]]},"references-count":2,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,2,28]]}},"URL":"https:\/\/doi.org\/10.1001\/jama.2022.22870","relation":{},"ISSN":["0098-7484"],"issn-type":[{"value":"0098-7484","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2,28]]}}}